We examined ten tumor specimens from breast cancer patients (aged 47–79) for presence and nature of TIL-B, first by PCR amplification of V(D)J antibody segments (CDR3, complementarity-determining region 3) and then by a comparison between IgG and IgA antibody classes presenting in tumor samples. Here, CD79A is linked to breast cancer.